List of Finacea drug patents
Finacea is owned by Leo Pharma As.
Finacea contains Azelaic Acid.
Finacea has a total of 8 drug patents out of which 0 drug patents have expired.
Finacea was authorised for market use on 29 July, 2015.
Finacea is available in aerosol, foam;topical dosage forms.
Finacea can be used as topical treatment of inflammatory papules and pustules of mild to moderate rosacea.
The generics of Finacea are possible to be released after 28 February, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900554 | LEO PHARMA AS | Foamable composition and uses thereof |
Oct, 2023
(8 months from now) | |
| US10322085 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Oct, 2023
(8 months from now) | |
| US8722021 | LEO PHARMA AS | Foamable carriers |
Oct, 2023
(8 months from now) | |
| US8435498 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Mar, 2024
(1 year, 1 month from now) | |
| US7700076 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Sep, 2027
(4 years from now) | |
| US10117812 | LEO PHARMA AS | Foamable composition combining a polar solvent and a hydrophobic carrier |
Oct, 2027
(4 years from now) | |
| US9265725 | LEO PHARMA AS | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
Dec, 2027
(4 years from now) | |
| US9211259 | LEO PHARMA AS | Antibiotic kit and composition and uses thereof |
Feb, 2029
(6 years from now) | |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM;TOPICAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic